SABS Company Profile and Key Details

Q: Who are the executives of SABS?

Dr. Edward D. Hamilton D.V.M.Co-Founder & Board ObserverMr. Russell P. Beyer C.M.A., M.B.A.Executive Vice President & Chief Financial OfficerDr. Christoph Bausch M.B.A., Ph.D.Executive Vice President & Chief Operating OfficerDr. Carlos N. Carillo Ph.D.Senior Vice President of Regulatory AffairsMr. Samuel J. ReichExecutive ChairmanDr. Eddie Joe Sullivan Ph.D.Co-Founder, Pres, Chief Executive Officer & DirectorMs. Christine E. Hamilton M.B.A.Co-Founder & Independent DirectorDr. Alexandra Kropotova M.B.A., M.D.Executive Vice President & Chief Medical Officer

NASDAQ : SABS

SAB Biotherapeutics

$3.31

-0.05-1.49%

At Close 4:00 PM

68.41

B+ESG ScoreESG Rating

Profile Key Stats Analyst Ratings Ownership Ratios Financials Dividend & splits Sentiment Forecast

Price Chart

Stock Price Today

SAB Biotherapeutics, Inc. (SABS) stock declined over -1.49%, trading at $3.31 on NASDAQ, down from the previous close of $3.36. The stock opened at $3.35, fluctuating between $3.31 and $3.45 in the recent session.

Stock Snapshot

3.36

Prev. Close

31.64M

Market Cap

3.31

Day Low

-5.71

P/E Ratio

-0.58

EPS (TTM)

-4.27

Cash Flow per Share

3.35

Open

9.56M

Number of Shares

3.45

Day High

72.52%

Free Float in %

9.67

Book Value

213.32K

Volume

Relevant Articles

SEC Fillings

Current Report (8-k)

Filing Date	Accepted Date

Annual Report (10-k)

Filing Date	Accepted Date

Stock Price History Chart

Date	Open	High	Low	Close	Volume
Jun 10, 2026	3.35	3.45	3.31	3.31	213.61K
Jun 09, 2026	3.40	3.50	3.35	3.36	362.65K
Jun 08, 2026	3.40	3.45	3.34	3.40	349.04K
Jun 05, 2026	3.47	3.47	3.28	3.38	351.62K
Jun 04, 2026	3.35	3.54	3.32	3.47	303.98K
Jun 03, 2026	3.47	3.49	3.32	3.36	326.71K
Jun 01, 2026	3.74	3.74	3.42	3.44	509.44K
May 29, 2026	3.56	3.65	3.52	3.60	223.67K
May 28, 2026	3.60	3.65	3.55	3.57	133.77K
May 27, 2026	3.80	3.84	3.59	3.60	283.23K
May 26, 2026	3.89	3.92	3.73	3.81	446.93K
May 22, 2026	3.85	3.97	3.84	3.90	324.01K
May 21, 2026	3.65	3.82	3.59	3.81	367.83K
May 20, 2026	3.70	3.85	3.66	3.68	565.64K
May 19, 2026	3.54	3.60	3.40	3.55	488.02K
May 18, 2026	3.68	3.74	3.44	3.56	772.5K
May 15, 2026	3.84	3.88	3.59	3.70	939.49K
May 14, 2026	4.00	4.13	3.78	3.89	712.73K
May 13, 2026	3.62	4.04	3.57	3.96	756.65K
May 12, 2026	3.80	3.81	3.54	3.62	835.68K

Contact Details

Sioux Falls, SD 57104

United States

https://www.sabbiotherapeutics.com 605 679 6980

About Company

SAB Biotherapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of immunotherapies based on human antibodies. It has applied advanced genetic engineering and antibody science to develop transchromosomic bovine herds that produce fully human antibodies targeted at specific diseases, including infectious diseases comprising COVID-19 and influenza, immune and autoimmune disorders, such as type 1 diabetes, organ transplantation, and cancer. The company uses its DiversitAb immunotherapy platform to produce fully-human polyclonal antibodies without the need for human donors. Its lead product candidates include SAB-185, a fully-human polyclonal antibody therapeutic candidate that is in Phase III clinical trial for the treatment of COVID-19; and SAB-176, a fully-human polyclonal antibody therapeutic candidate that is in development to treat or prevent severe influenza. The company's pre-clinical product candidates in development for autoimmune diseases include SAB-142 for type 1 diabetes and organ transplant induction/rejection. The company was founded in 2014 and is based in Sioux Falls, South Dakota.

Stock Peers

ARGX

-21.82-2.47%

argenx SE$862.18 REGN

-14.53-2.36%

Regeneron Pharmaceuticals, Inc.$601.65 UTHR

-9.04-1.63%

United Therapeutics Corporation$544.10 MDGL

-5.57-1.17%

Madrigal Pharmaceuticals, Inc.$471.32 VRTX

-10.06-2.26%

Vertex Pharmaceuticals Incorporated$435.71 KRTX

0.09+0.03%

Karuna Therapeutics, Inc.$329.83 KRYS

2.66+0.86%

Krystal Biotech, Inc.$312.41 ALNY

-6.47-2.17%

Alnylam Pharmaceuticals, Inc.$291.22 LGND

4.96+2.04%

Ligand Pharmaceuticals Incorporated$248.24 AXSM

0.7+0.28%

Axsome Therapeutics, Inc.$246.34

Frequently Asked Questions

What is the current SAB Biotherapeutics, Inc. (SABS) stock price?

SAB Biotherapeutics, Inc. (NASDAQ: SABS) stock price is $3.31 in the last trading session. During the trading session, SABS stock reached the peak price of $3.45 while $3.31 was the lowest point it dropped to. The percentage change in SABS stock occurred in the recent session was -1.49% while the dollar amount for the price change in SABS stock was - $0.05.

SABS's industry and sector of operation?

The NASDAQ listed SABS is part of Biotechnology industry that operates in the broader Healthcare sector. SAB Biotherapeutics, Inc. designs, manufactures, and markets smartphones, personal computers, tablets, wearables, and accessories worldwide.

Who are the executives of SABS?

Dr. Edward D. Hamilton D.V.M.
Co-Founder & Board Observer
Mr. Russell P. Beyer C.M.A., M.B.A.
Executive Vice President & Chief Financial Officer
Dr. Christoph Bausch M.B.A., Ph.D.
Executive Vice President & Chief Operating Officer
Dr. Carlos N. Carillo Ph.D.
Senior Vice President of Regulatory Affairs
Mr. Samuel J. Reich
Executive Chairman
Dr. Eddie Joe Sullivan Ph.D.
Co-Founder, Pres, Chief Executive Officer & Director
Ms. Christine E. Hamilton M.B.A.
Co-Founder & Independent Director
Dr. Alexandra Kropotova M.B.A., M.D.
Executive Vice President & Chief Medical Officer

How SABS did perform over past 52-week?

SABS's closing price is 106.88% higher than its 52-week low of $1.60 where as its distance from 52-week high of $6.60 is -49.85%.

How many employees does SABS have?

Number of SABS employees currently stands at 63.

Link for SABS official website?

Official Website of SABS is: https://www.sabbiotherapeutics.com

How do I contact SABS?

SABS could be contacted at phone 605 679 6980 and can also be accessed through its website. SABS operates from 2100 East 54th Street North, Sioux Falls, SD 57104, United States.

How many shares of SABS are traded daily?

SABS stock volume for the day was 213.32K shares. The average number of SABS shares traded daily for last 3 months was 736.95K.

What is the market cap of SABS currently?

The market value of SABS currently stands at $31.64M with its latest stock price at $3.31 and 9.56M of its shares outstanding.

Stocks Telegraph provides information and tools designed to assist investors and Wall Street players. A major goal is to offer financiers comprehensive information that will help them gain insight into investing.

Stocks Telegraph does not provide any advice or recommendations for buying or selling stocks, securities, or other financial products. Information contained on this website is for informational purposes only and should not be construed as professional financial, investment or other advice. Stocks Telegraph is not liable for any loss or damage that may occur as a result of reliance on this data.

Employees	63
Beta	0.61
Sales or Revenue	$2.24M
5Y Sales Change%	4.122%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

Employees	63
Beta	0.61
Sales or Revenue	$2.24M
5Y Sales Change%	4.122%
Fiscal Year Ends	December
Sector	Healthcare
Industry	Biotechnology

SABS Company Profile and Key Details

SAB Biotherapeutics

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Frequently Asked Questions

Price Chart

Stock Price Today

Stock Snapshot

Relevant Articles

SEC Fillings

Current Report (8-k)

Annual Report (10-k)

Stock Price History Chart

Contact Details

About Company

Company Information

Stock Peers

Company Overview

Technical Performance

Valuation Metrics

Dividend & Fair Value

Earnings & Analyst Outlook

Shareholding & Insider Activity

Financial & Profitability Overview

Quarterly Financial Highlights

Price Forecast & Outlook

Key Takeaways

Frequently Asked Questions

Shareholding & Insider Activity

Technical Performance

Financial & Profitability Overview

Quarterly Financial Highlights

Earnings & Analyst Outlook

Dividend & Fair Value

Company Overview

Valuation Metrics

Price Forecast & Outlook

Key Takeaways